AIM: The incidence of adverse drug events (ADEs) in surgical and non-surgical patients may differ. This individual patient data meta-analysis (IPDMA) identifies patient characteristics and types of medication most associated with patients experiencing ADEs and suggests target areas for reducing harm and implementing focused interventions. METHODS: Authors of eligible studies on preventable ADEs (pADEs) were approached for collaboration. For assessment of differences among (non-)surgical patients and identification of associated factors descriptive statistics, Pearson chi-square, Poisson and logistic regression analyses were performed. For identification of high risk drugs (HRDs), a model was developed based on frequency, severity and preventability of medication related to ADEs. RESULTS: Included were 5367 patients from four studies. Patients aged ≥ 77 years experienced more ADEs and pADEs compared with patients aged ≤ 52 years (odds ratios (OR) 2.12 (95% CI 1.70, 2.65) and 2.55 (95% CI 1.70, 3.84), respectively, both P < 0.05). Polypharmacy on admission also increased the risk of ADEs (OR 1.21 (95% CI 1.03, 1.44), P < 0.05) and pADEs (OR 1.85 (95% CI 1.34, 2.56), P < 0.05). pADEs were associated with more severe harm than non-preventable ADEs (54% vs. 32%, P < 0.05). The top five HRDs were antibiotics, sedatives, anticoagulants, diuretics and antihypertensives. Events associated with HRDs included diarrhoea or constipation, abnormal liver function test and central nervous system events. Most pADEs resulted from prescribing errors (90%). CONCLUSION: Elderly patients with polypharmacy on admission and receiving antibiotics, sedatives, anticoagulants, diuretics or antihypertensives were more prone to experiencing ADEs. Efficiency in prevention of ADEs may be improved by targeted vigilance systems for alertness of physicians and pharmacists.
AIM: The incidence of adverse drug events (ADEs) in surgical and non-surgical patients may differ. This individual patient data meta-analysis (IPDMA) identifies patient characteristics and types of medication most associated with patients experiencing ADEs and suggests target areas for reducing harm and implementing focused interventions. METHODS: Authors of eligible studies on preventable ADEs (pADEs) were approached for collaboration. For assessment of differences among (non-)surgical patients and identification of associated factors descriptive statistics, Pearson chi-square, Poisson and logistic regression analyses were performed. For identification of high risk drugs (HRDs), a model was developed based on frequency, severity and preventability of medication related to ADEs. RESULTS: Included were 5367 patients from four studies. Patients aged ≥ 77 years experienced more ADEs and pADEs compared with patients aged ≤ 52 years (odds ratios (OR) 2.12 (95% CI 1.70, 2.65) and 2.55 (95% CI 1.70, 3.84), respectively, both P < 0.05). Polypharmacy on admission also increased the risk of ADEs (OR 1.21 (95% CI 1.03, 1.44), P < 0.05) and pADEs (OR 1.85 (95% CI 1.34, 2.56), P < 0.05). pADEs were associated with more severe harm than non-preventable ADEs (54% vs. 32%, P < 0.05). The top five HRDs were antibiotics, sedatives, anticoagulants, diuretics and antihypertensives. Events associated with HRDs included diarrhoea or constipation, abnormal liver function test and central nervous system events. Most pADEs resulted from prescribing errors (90%). CONCLUSION: Elderly patients with polypharmacy on admission and receiving antibiotics, sedatives, anticoagulants, diuretics or antihypertensives were more prone to experiencing ADEs. Efficiency in prevention of ADEs may be improved by targeted vigilance systems for alertness of physicians and pharmacists.
Authors: Eefje N de Vries; Hubert A Prins; Rogier M P H Crolla; Adriaan J den Outer; George van Andel; Sven H van Helden; Wolfgang S Schlack; M Agnès van Putten; Dirk J Gouma; Marcel G W Dijkgraaf; Susanne M Smorenburg; Marja A Boermeester Journal: N Engl J Med Date: 2010-11-11 Impact factor: 91.245
Authors: Anita Krähenbühl-Melcher; Raymond Schlienger; Markus Lampert; Manuel Haschke; Jürgen Drewe; Stephan Krähenbühl Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Maya A Ramrattan; Eveline B Boeker; Kim Ram; Desiree M T Burgers; Monica de Boer; Loraine Lie-A-Huen; Wilhelmina M C Mulder; Marja A Boermeester Journal: Int J Clin Pharm Date: 2014-04-20
Authors: Joanna E Klopotowska; Peter C Wierenga; Susanne M Smorenburg; Clementine C M Stuijt; Lambertus Arisz; Paul F M Kuks; Marcel G W Dijkgraaf; Loraine Lie-A-Huen; Sophia E de Rooij Journal: Eur J Clin Pharmacol Date: 2012-06-07 Impact factor: 2.953
Authors: Kay Seden; Jamie J Kirkham; Tom Kennedy; Michael Lloyd; Sally James; Aine McManus; Andrew Ritchings; Jennifer Simpson; Dave Thornton; Andrea Gill; Carolyn Coleman; Bethan Thorpe; Saye H Khoo Journal: BMJ Open Date: 2013-01-09 Impact factor: 2.692
Authors: Frank Moriarty; Caitriona Cahir; Kathleen Bennett; Carmel M Hughes; Rose Anne Kenny; Tom Fahey Journal: BMJ Open Date: 2017-10-16 Impact factor: 2.692
Authors: Jacqueline M Bos; Stephanie Natsch; Patricia M L A van den Bemt; Johan L W Pot; J Elsbeth Nagtegaal; Andre Wieringa; Gert Jan van der Wilt; Peter A G M De Smet; Cornelis Kramers Journal: Int J Clin Pharm Date: 2017-11-03